155 related articles for article (PubMed ID: 11510469)
1. The t(4;14)(p16.3;q32) is strongly associated with chromosome 13 abnormalities in both multiple myeloma and monoclonal gammopathy of undetermined significance.
Fonseca R; Oken MM; Greipp PR;
Blood; 2001 Aug; 98(4):1271-2. PubMed ID: 11510469
[No Abstract] [Full Text] [Related]
2. t(4;14)(p16.3;q32) is strongly associated with a shorter survival in myeloma patients.
Winkler JM; Greipp P; Fonseca R
Br J Haematol; 2003 Jan; 120(1):170-1. PubMed ID: 12492597
[No Abstract] [Full Text] [Related]
3. Genomic abnormalities in monoclonal gammopathy of undetermined significance.
Fonseca R; Bailey RJ; Ahmann GJ; Rajkumar SV; Hoyer JD; Lust JA; Kyle RA; Gertz MA; Greipp PR; Dewald GW
Blood; 2002 Aug; 100(4):1417-24. PubMed ID: 12149226
[TBL] [Abstract][Full Text] [Related]
4. Timing of acquisition of deletion 13 in plasma cell dyscrasias is dependent on genetic context.
Chiecchio L; Dagrada GP; Ibrahim AH; Dachs Cabanas E; Protheroe RK; Stockley DM; Orchard KH; Cross NC; Harrison CJ; Ross FM;
Haematologica; 2009 Dec; 94(12):1708-13. PubMed ID: 19996118
[TBL] [Abstract][Full Text] [Related]
5. FGFR3 dysregulation and clinical outcome in myeloma.
Rasmussen T; Hudlebusch HR; Knudsen LM; Johnsen HE
Br J Haematol; 2003 Jan; 120(1):166. PubMed ID: 12492593
[No Abstract] [Full Text] [Related]
6. Characterization of the t(4;14)(p16.3;q32) in the KMS-18 multiple myeloma cell line.
Ronchetti D; Bogni S; Finelli P; Lombardi L; Otsuki T; Maiolo AT; Neri A
Leukemia; 2001 May; 15(5):864-5. PubMed ID: 11368454
[No Abstract] [Full Text] [Related]
7. Identification of a novel IGH-MMSET fusion transcript in a human myeloma cell line with the t(4;14)(p16.3;q32) chromosomal translocation.
Intini D; Fabris S; Storlazzi T; Otsuki T; Ciceri G; Verdelli D; Lombardi L; Rocchi M; Neri A
Br J Haematol; 2004 Aug; 126(3):437-9. PubMed ID: 15257719
[No Abstract] [Full Text] [Related]
8. 14q32 translocations and monosomy 13 observed in monoclonal gammopathy of undetermined significance delineate a multistep process for the oncogenesis of multiple myeloma. Intergroupe Francophone du Myélome.
Avet-Loiseau H; Facon T; Daviet A; Godon C; Rapp MJ; Harousseau JL; Grosbois B; Bataille R
Cancer Res; 1999 Sep; 59(18):4546-50. PubMed ID: 10493504
[TBL] [Abstract][Full Text] [Related]
9. Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3.
Chesi M; Nardini E; Brents LA; Schröck E; Ried T; Kuehl WM; Bergsagel PL
Nat Genet; 1997 Jul; 16(3):260-4. PubMed ID: 9207791
[TBL] [Abstract][Full Text] [Related]
10. In multiple myeloma, t(4;14)(p16;q32) is an adverse prognostic factor irrespective of FGFR3 expression.
Keats JJ; Reiman T; Maxwell CA; Taylor BJ; Larratt LM; Mant MJ; Belch AR; Pilarski LM
Blood; 2003 Feb; 101(4):1520-9. PubMed ID: 12393535
[TBL] [Abstract][Full Text] [Related]
11. Expression of fibroblast growth factor and FGF-receptor family genes in human myeloma cells, including lines possessing t(4;14)(q16.3;q32. 3) and FGFR3 translocation.
Otsuki T; Yamada O; Yata K; Sakaguchi H; Kurebayashi J; Nakazawa N; Taniwaki M; Yawata Y; Ueki A
Int J Oncol; 1999 Dec; 15(6):1205-12. PubMed ID: 10568829
[TBL] [Abstract][Full Text] [Related]
12. Mutation, SNP, and isoform analysis of fibroblast growth factor receptor 3 (FGFR3) in 150 newly diagnosed multiple myeloma patients.
Onwuazor ON; Wen XY; Wang DY; Zhuang L; Masih-Khan E; Claudio J; Barlogie B; Shaughnessy JD; Stewart AK
Blood; 2003 Jul; 102(2):772-3. PubMed ID: 12835230
[No Abstract] [Full Text] [Related]
13. The progression from MGUS to smoldering myeloma and eventually to multiple myeloma involves a clonal expansion of genetically abnormal plasma cells.
López-Corral L; Gutiérrez NC; Vidriales MB; Mateos MV; Rasillo A; García-Sanz R; Paiva B; San Miguel JF
Clin Cancer Res; 2011 Apr; 17(7):1692-700. PubMed ID: 21325290
[TBL] [Abstract][Full Text] [Related]
14. Characterization of oncogene dysregulation in multiple myeloma by combined FISH and DNA microarray analyses.
Fabris S; Agnelli L; Mattioli M; Baldini L; Ronchetti D; Morabito F; Verdelli D; Nobili L; Intini D; Callea V; Stelitano C; Lombardi L; Neri A
Genes Chromosomes Cancer; 2005 Feb; 42(2):117-27. PubMed ID: 15543617
[TBL] [Abstract][Full Text] [Related]
15. Analysis of FGFR3 gene mutations in multiple myeloma patients with t(4;14).
Intini D; Baldini L; Fabris S; Lombardi L; Ciceri G; Maiolo AT; Neri A
Br J Haematol; 2001 Aug; 114(2):362-4. PubMed ID: 11529856
[TBL] [Abstract][Full Text] [Related]
16. A novel mutation involving the carboxy terminal region of the FGFR3 gene in a multiple myeloma patient with t(4;14).
Intini D; Baldini L; Lombardi L; Neri A
Leukemia; 2002 Jun; 16(6):1201-2. PubMed ID: 12040455
[No Abstract] [Full Text] [Related]
17. The Ig heavy chain gene is frequently involved in chromosomal translocations in multiple myeloma and plasma cell leukemia as detected by in situ hybridization.
Nishida K; Tamura A; Nakazawa N; Ueda Y; Abe T; Matsuda F; Kashima K; Taniwaki M
Blood; 1997 Jul; 90(2):526-34. PubMed ID: 9226151
[TBL] [Abstract][Full Text] [Related]
18. FGFR3 gene mutations associated with human skeletal disorders occur rarely in multiple myeloma.
Fracchiolla NS; Luminari S; Baldini L; Lombardi L; Maiolo AT; Neri A
Blood; 1998 Oct; 92(8):2987-9. PubMed ID: 9763594
[No Abstract] [Full Text] [Related]
19. A subset of multiple myeloma harboring the t(4;14)(p16;q32) translocation lacks FGFR3 expression but maintains an IGH/MMSET fusion transcript.
Santra M; Zhan F; Tian E; Barlogie B; Shaughnessy J
Blood; 2003 Mar; 101(6):2374-6. PubMed ID: 12433679
[TBL] [Abstract][Full Text] [Related]
20. Deregulated FGFR3 mutants in multiple myeloma cell lines with t(4;14): comparative analysis of Y373C, K650E and the novel G384D mutations.
Ronchetti D; Greco A; Compasso S; Colombo G; Dell'Era P; Otsuki T; Lombardi L; Neri A
Oncogene; 2001 Jun; 20(27):3553-62. PubMed ID: 11429702
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
